1. Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL).
- Author
-
Yokota R, Hashimoto S, Watanabe I, Kishimoto S, Toyama M, Okamoto M, Yoshimitsu M, Ishitsuka K, Ito Y, and Baba M
- Subjects
- Adult, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Female, Humans, Jurkat Cells, Leukemia-Lymphoma, Adult T-Cell therapy, Male, Middle Aged, CD27 Ligand antagonists & inhibitors, Immunoconjugates pharmacology, Leukemia-Lymphoma, Adult T-Cell immunology, Maytansine pharmacology, Single-Chain Antibodies pharmacology
- Abstract
Background/aim: Adult T-cell leukemia (ATL) is a hematological malignancy caused by infection with human T-cell leukemia virus type 1 (HTLV-1). Chemotherapy, antibody therapy, and bone marrow transplantation are used to treat this disease, however, median survival time has not been significantly improved. Our aim was to develop and evaluate a novel antibody-drug conjugate (ADC) with regards to cell cytotoxicity and target specificity., Materials and Methods: In this study, we have constructed a novel ADC, which is composed of an anti-CD70 single chain Fv-Fc antibody conjugated with the anticancer agent emtansine using a novel antibody modification method. Cell cytotoxicity and target specificity were assessed using a cell proliferation assay., Results: The anti-CD70 ADC selectively killed HTLV-1-infected cells and ATL cells without affecting other cells., Conclusion: The anti-CD70 ADC offers some chemotherapeutic potential for the treatment of ATL., (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF